$41.83
2.33% day before yesterday
Nasdaq, Jan 02, 10:04 pm CET
ISIN
US7665596034
Symbol
RIGL

Rigel Pharmaceuticals, Inc. Stock price

$41.83
-2.58 5.81% 1M
+23.18 124.29% 6M
-1.00 2.33% YTD
+24.51 141.51% 1Y
+26.83 178.87% 3Y
+7.13 20.55% 5Y
+13.23 46.26% 10Y
-41.77 49.96% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-1.00 2.33%
ISIN
US7665596034
Symbol
RIGL
Industry

Key metrics

Basic
Market capitalization
$759.3m
Enterprise Value
$681.9m
Net debt
positive
Cash
$137.1m
Shares outstanding
18.1m
Valuation (TTM | estimate)
P/E
7.1 | 6.3
P/S
2.7 | 2.6
EV/Sales
2.4 | 2.3
EV/FCF
10.0
P/B
6.5
Financial Health
Equity Ratio
2.0%
Return on Equity
531.8%
ROCE
80.3%
ROIC
180.9%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$282.1m | $296.8m
EBITDA
$121.4m | $126.1m
EBIT
$119.0m | $126.6m
Net Income
$113.3m | $121.3m
Free Cash Flow
$68.1m
Growth (TTM | estimate)
Revenue
79.1% | 65.5%
EBITDA
962.8% | 377.3%
EBIT
1,151.7% | 423.2%
Net Income
2,820.1% | 593.5%
Free Cash Flow
557.7%
Margin (TTM | estimate)
Gross
93.1%
EBITDA
43.0% | 42.5%
EBIT
42.2%
Net
40.2% | 40.9%
Free Cash Flow
24.2%
More
EPS
$5.9
FCF per Share
$3.8
Short interest
16.0%
Employees
163
Rev per Employee
$1.1m
Show more

Is Rigel Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Rigel Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

8x Buy
67%
4x Hold
33%

Analyst Opinions

12 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Rigel Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
282 282
79% 79%
100%
- Direct Costs 19 19
17% 17%
7%
263 263
86% 86%
93%
- Selling and Administrative Expenses 115 115
5% 5%
41%
- Research and Development Expense 28 28
35% 35%
10%
121 121
963% 963%
43%
- Depreciation and Amortization 2.42 2.42
27% 27%
1%
EBIT (Operating Income) EBIT 119 119
1,152% 1,152%
42%
Net Profit 113 113
2,820% 2,820%
40%

In millions USD.

Don't miss a Thing! We will send you all news about Rigel Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rigel Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
2 days ago
Rigel Pharmaceuticals delivered strong 2025 results, with Q3 revenue of $69.5M, net income of $27.9M, and cash of $137.1M. RIGL raised 2025 revenue guidance to $285M–$290M, projecting 55%–59% commercial growth, driven by TAVALISSE, REZLIDHIA, and GAVRETO. 2026 is expected to be a transition year, with flat revenue and declining EPS due to higher R&D spend, before a return to double-digit growth...
Neutral
PRNewsWire
27 days ago
R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD, including 40% (2/5) in the 500 mg BID dose group SOUTH SAN FRANCISCO, Calif. , Dec. 7, 2025 /PRNewswire/ -- Rigel Pharmaceu...
Positive
Seeking Alpha
about one month ago
Rigel Pharma is a profitable biotech with three FDA-approved drugs, experiencing accelerating revenue growth led by Tavalisse's strong performance. RIGL trades at a significant discount to biotech peers, despite a 186% YTD stock rise and robust 2025 sales guidance, making it a contrarian BUY. Continued momentum in Tavalisse and emerging growth from Rezlidhia position RIGL for potential outperfo...
More Rigel Pharmaceuticals, Inc. News

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Head office United States
CEO Raul Rodriguez
Employees 163
Founded 1996
Website www.rigel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today